Abstract
The article presents and analyzes the effect of combined therapy of atorvastatin and essential phospholipids in patients with rheumatoid arthritis (RA) and lipid metabolism indicators in non-alcoholic fatty liver disease (NAFLD). We examined and treated 77 RA patients with NAFLD (64 women (83.1%) and 13 men (16.9%)), under the age of 55 years old. The patients were divided into 3 groups. Additionally to RA antirheumatic therapy, the first group (n=25) received atorvastatin, the second group (n=26) - essential phospholipids, and the third group (n=26) - a combination of atorvastatin and essential phospholipids for 6 months. Assessment of the state of lipid metabolism was carried out by studying the laboratory indices of a lipid profile. A hypolipidemic effect was revealed when using both atorvastatin and essential phospholipids in patients with RA NAFLD, which increases with their combined use. Whereas the levels of total cholesterol, triglycerides (TG), low-density lipoprotein (LDL) cholesterol, and very-low-density lipoprotein (VLDL) cholesterol levels in the blood serum significantly decrease with a simultaneous increase in the content of high-density lipoproteins (HDL) cholesterol. We revealed pronounced hypolipidemic and hepatoprotective effects in RA patients with NAFLD due to combined use of atorvastatin and essential phospholipids.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
